Eli Lilly’s donanemab slows Alzheimer’s in phase 3 trial 04-May-2023 By Jonathan Smith The antibody drug donanemab, developed by the pharma giant Eli Lilly, has met all of its goals in a phase 3 trial for slowing cognitive decline in people with Alzheimer’s disease.